VanEck Pharmaceutical ETF $PPH Stock Holdings Increased by UBS Group AG

UBS Group AG raised its holdings in shares of VanEck Pharmaceutical ETF (NASDAQ:PPH) by 145.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 107,379 shares of the company’s stock after acquiring an additional 63,692 shares during the period. UBS Group AG’s holdings in VanEck Pharmaceutical ETF were worth $11,078,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in PPH. Royal Bank of Canada raised its stake in VanEck Pharmaceutical ETF by 53.3% during the 1st quarter. Royal Bank of Canada now owns 67,596 shares of the company’s stock valued at $6,160,000 after acquiring an additional 23,491 shares in the last quarter. NewEdge Advisors LLC raised its stake in VanEck Pharmaceutical ETF by 7.3% during the 1st quarter. NewEdge Advisors LLC now owns 8,873 shares of the company’s stock valued at $809,000 after acquiring an additional 607 shares in the last quarter. Qube Research & Technologies Ltd raised its stake in VanEck Pharmaceutical ETF by 13,856.9% during the 2nd quarter. Qube Research & Technologies Ltd now owns 16,190 shares of the company’s stock valued at $1,424,000 after acquiring an additional 16,074 shares in the last quarter. Raymond James Financial Inc. raised its stake in VanEck Pharmaceutical ETF by 11.8% during the 2nd quarter. Raymond James Financial Inc. now owns 22,417 shares of the company’s stock valued at $1,972,000 after acquiring an additional 2,363 shares in the last quarter. Finally, Two Sigma Securities LLC raised its stake in VanEck Pharmaceutical ETF by 40.1% during the 2nd quarter. Two Sigma Securities LLC now owns 4,480 shares of the company’s stock valued at $394,000 after acquiring an additional 1,282 shares in the last quarter.

VanEck Pharmaceutical ETF Price Performance

Shares of VanEck Pharmaceutical ETF stock opened at $100.84 on Friday. The business’s fifty day moving average price is $102.77 and its two-hundred day moving average price is $103.16. The company has a market capitalization of $956.97 million, a P/E ratio of 20.21 and a beta of 0.46. VanEck Pharmaceutical ETF has a 1-year low of $81.74 and a 1-year high of $112.58.

VanEck Pharmaceutical ETF Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, April 7th. Stockholders of record on Wednesday, April 1st were paid a $0.8441 dividend. The ex-dividend date of this dividend was Wednesday, April 1st. This represents a $3.38 dividend on an annualized basis and a dividend yield of 3.3%. This is a boost from VanEck Pharmaceutical ETF’s previous quarterly dividend of $0.31.

VanEck Pharmaceutical ETF Profile

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.